Hexagon Nutrition quarterly results show 15.2 per cent revenue growth, lower profit as shares gain
Hexagon Nutrition reported Q2 FY27 revenue growth of 15.2 per cent, while profit declined 19 per cent as margins contracted. Shares traded higher on November 17, 2026, despite weaker earnings conversion.
✨ Key Takeaways
Hexagon Nutrition reported consolidated revenue of Rs 109.66 crore for Q2 FY27, up 15.2 per cent YoY, while profit after Tax (PAT) fell 19 per cent to Rs 8.17 crore. Shares were up 6.77 per cent on November 17, 2026. The Quarterly Results highlighted continued sales expansion but weaker conversion of revenue into earnings.
Earnings before interest, tax, depreciation and amortisation (EBITDA) declined 11.28 per cent to Rs 10.86 crore. EBITDA margin narrowed by 296 basis points to 9.90 per cent, while PAT margin slipped to 7.45 per cent from 10.65 per cent. Revenue increased 5.1 per cent QoQ, although profit was only marginally higher.
Expense trends underline the profitability challenge. Materials consumed rose to Rs 70.36 crore from Rs 43.01 crore a year earlier, and employee benefit expenses increased to Rs 16.14 crore from Rs 12.70 crore. Other expenses declined, but profit before tax still fell 23.90 per cent.
For the half year ended September 30, 2026, revenue rose 27.33 per cent to Rs 213.97 crore. EBITDA increased just 1.61 per cent to Rs 22.66 crore, while PAT edged down to Rs 16.24 crore. This contrasts with FY26, when annual revenue grew 17.8 per cent and PAT increased 56.1 per cent.
Hexagon supplies customised micronutrient premixes, branded clinical and wellness nutrition, and therapeutic products for institutional customers. Its premix business grew 47.7 per cent in Q2, while branded nutrition grew 29 per cent. Management aims to expand domestic distribution, deepen smaller-city penetration and increase branded exports.
Chairman and Executive Director Arun Kelkar said improving operational efficiencies and strengthening profitability remain priorities. The company's medium-term EBITDA margin target exceeds 15 per cent, substantially above its first-half margin of 10.59 per cent.
Key Positives
- Both premix and branded nutrition maintained strong growth, supporting expansion across different customer groups.
- Revenue advanced sequentially, extending the first quarter's sales momentum.
Key Negatives
- Profitability weakened despite higher sales, with both operating and net margins contracting.
- Inventories rose to Rs 136.15 crore from Rs 83.90 crore at FY26 end, while short-term borrowings increased to Rs 32.74 crore from Rs 24.50 crore.
At 2.22 pm on November 17, 2026, Hexagon Nutrition shares traded at Rs 63.99, against the previous close of Rs 59.93. The price remained about 16.5 per cent below its 52-week high of Rs 76.68, within a yearly range that bottomed at Rs 51.12. The day's advance therefore left the shares below their recent peak, even as the latest earnings showed pressure on profitability.
Hexagon Nutrition's Growth Needs Better Earnings Conversion
For Hexagon, the key issue is no longer simply whether demand can expand. Premix and branded nutrition are delivering growth, but the latest quarter shows that higher sales alone are not restoring profitability. Expanding branded distribution and using manufacturing capacity more effectively could help, provided additional revenue absorbs selling costs and improves the product mix. The medium-term margin aspiration remains an execution target rather than an established earnings trajectory.
The investment implications are mixed. Revenue momentum supports the expansion strategy, while rising inventory and short-term borrowing increase the importance of cash conversion. Subsequent results need to demonstrate that inventory translates into dispatches and collections, alongside better operating margins. A sustained recovery in profit growth without a disproportionate increase in working capital would provide stronger evidence that Hexagon's expansion is becoming financially productive.
Disclaimer: The article is for informational purposes only and not investment advice.
